Series of SMZL patients treated with splenectomy
| Reference . | Year . | N . | Response . | OS . | Deaths due to surgery . | |
|---|---|---|---|---|---|---|
| ORR (%) . | Duration . | |||||
| Mulligan et al68 | 1991 | 20 | 95 | Median DOR 4 y | NR | 1 |
| Troussard et al59 | 1996 | 28 | 75 | NR | 71% at 5 y | 1 |
| Chacon et al61 | 2002 | 60∗ | 93.3 | Median FFS 40 mo | 65% at 5 y | NR |
| Thieblemont et al1 | 2002 | 48† | 100 | PFS 48% at 5 y | NR | NR |
| Parry-Jones et al60 | 2003 | 33 | NR | NR | LSS 95% at 10 y | NR |
| Iannitto et al69 | 2004 | 21 | 91 | Median DOR 4 y | NR | NR |
| Tsimberidou et al70 | 2006 | 10 | 60 | FFS 80% at 3 y | 89% at 3 y | 0 |
| Olszewski et al71 | 2012 | 652 | NR | NR | 67.8% at 5 y‡ | NR |
| Kalpadakis et al73 | 2013 | 27 | 85 | PFS 58% at 5 y | 77% at 5 y | 1 |
| Lenglet et al7 | 2014 | 100 | 97 | PFS 61% at 5 y | 84% at 5 y | 0 |
| Xing et al62 | 2015 | 52§ | NR | FFS 39% at 10 y | 61% at 10 y | 0 |
| Pata et al89 | 2015 | 41 | 90 | PFS 35% at 5 y | 75% at 5 y | 0 |
| Reference . | Year . | N . | Response . | OS . | Deaths due to surgery . | |
|---|---|---|---|---|---|---|
| ORR (%) . | Duration . | |||||
| Mulligan et al68 | 1991 | 20 | 95 | Median DOR 4 y | NR | 1 |
| Troussard et al59 | 1996 | 28 | 75 | NR | 71% at 5 y | 1 |
| Chacon et al61 | 2002 | 60∗ | 93.3 | Median FFS 40 mo | 65% at 5 y | NR |
| Thieblemont et al1 | 2002 | 48† | 100 | PFS 48% at 5 y | NR | NR |
| Parry-Jones et al60 | 2003 | 33 | NR | NR | LSS 95% at 10 y | NR |
| Iannitto et al69 | 2004 | 21 | 91 | Median DOR 4 y | NR | NR |
| Tsimberidou et al70 | 2006 | 10 | 60 | FFS 80% at 3 y | 89% at 3 y | 0 |
| Olszewski et al71 | 2012 | 652 | NR | NR | 67.8% at 5 y‡ | NR |
| Kalpadakis et al73 | 2013 | 27 | 85 | PFS 58% at 5 y | 77% at 5 y | 1 |
| Lenglet et al7 | 2014 | 100 | 97 | PFS 61% at 5 y | 84% at 5 y | 0 |
| Xing et al62 | 2015 | 52§ | NR | FFS 39% at 10 y | 61% at 10 y | 0 |
| Pata et al89 | 2015 | 41 | 90 | PFS 35% at 5 y | 75% at 5 y | 0 |
DOR, duration of response; FFS, failure-free survival; LSS, lymphoma-specific survival; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
Splenectomy alone in 29 patients.
Splenectomy alone in 25 patients.
Survival of entire series of 1251 patients with no impact of splenectomy on OS.
Splenectomy alone in 42 patients.